Skip to main content

tapinarof

Generic: TAPINAROF·Brand: VTAMA, Vtama

tapinarof: 6 clinical trials tracked.

tapinarof evidence translation

What we can confirm

6 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about tapinarof, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 2 study sponsors
Clinical Trials (6)

A Randomized, Double-Blind, Vehicle-Controlled (Period 1) and Open-Label (Period 2) Phase 3 Study to Investigate the Safety and Efficacy of Tapinarof Cream, 1% in Pediatric Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

NCT07265479·Phase 3·OGN
Active, not recruiting

Primary endpoint: Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8

InterventionalRandomizedquadruple187 enrolledStarted 2025-12Completion 2027-0846 sites · Canada, United StatesOrganon and Co

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site, Clinical Study to Evaluate the Therapeutic Equivalence of Tapinarof Cream 1% (Teva Pharmaceuticals, Inc.) With VTAMA® Tapinarof (Tapinarof) Cream 1% (Dermavant Sciences, Inc.) in Adult Patients With Plaque Psoriasis

NCT06742957·Phase 3·TEVJF
Completed

Primary endpoint: Primary change in the Physician Global Assessment (PGA)

InterventionalRandomizedquadruple560 enrolledStarted 2024-12Completion 2025-1126 sites · United StatesTeva Pharmaceuticals USA

An Open-label, Phase II Study to Evaluate the Clinical Efficacy and Safety of Tapinarof for Adult Patients With Palmoplantar Keratoderma

NCT06561321·Phase 2
Active, not recruiting

Primary endpoint: Physician's Global Assessment (PGA)

Interventionalopen6 targetStarted 2024-10Completion 2027-121 site · United StatesIndiana University

A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

NCT05172726·Phase 3·OGN
Active, not recruiting

Primary endpoint: Adverse Events (AEs) and Serious Adverse Events (SAEs)

Interventionalopen58 targetStarted 2021-12Completion 2026-1019 sites · Canada, United StatesOrganon and Co

A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults

NCT03983980·Phase 3·OGN
Completed

Primary endpoint: Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation

InterventionalRandomizedtriple515 enrolledStarted 2019-06Completion 2020-0550 sites · Canada, United StatesOrganon and Co

A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults

NCT03956355·Phase 3·OGN
Completed

Primary endpoint: Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation

InterventionalRandomizedquadruple510 enrolledStarted 2019-05Completion 2020-0550 sites · Canada, United StatesOrganon and Co